Date: Nov. 6, 2026, 9:00-18:00
Venue: Tigermed Headquarter Building, Hangzhou, Zhejiang Province,China
Theme: China-Korea BioInnovation, Clinical Practice, BD and Investment Cooperation
Format: Keynote Speeches + Project Roadshows by 12 Korean Companies + 1 to 1 Business Meetings
Organizers: Tigermed, DreamCIS (Korea), Angine Bio, HLC Fund
Registration: No Registration Fee but Open only to the pharmaceutical enterprises and investment body/Fund with the investment or BD partnership intention.
*As the head of BD or investment body with the focus on the innovation drugs, you can register by the following QR Code or you can write the emial via bd@angineglobal.com for additional information for the CKBF2026
Conference Agenda
09:00-09:30 Conference Registration
09:30-09:40 Opening Remarks
09:40-10:00
Introduction of Participating Chinese & Korean Enterprises and CKBF Event
Speaker: Yujin Paek, BD Director, DreamCIS (Korea)
10:00-10:30
China Biopharma Innovation and International BD Cooperation Trends
Speaker: Leo Luo, Founding Partner, Angine HPP Innovation Center and CKBF China Head
10:30-11:00
Perspectives from Investment Funds on Global Innovation Investment & ChinaKorea Biopharma Cooperation
Speaker: Runxie Lee, Director, HLC Fund
11:00-12:00
Innovation Project Roadshows by 4 Korean Companies (15 minutes per company)
-11:00-11:15
Project 1: arti-sRRV™-based split-genome retroviral replicating vector platform for recurrent glioblastoma and retinoblastoma (paediatric, orphan-drug indication).
Key Words: Immuno-gene therapy | Solid tumour | IND-stage
-11:15-11:30
Project 2: Novel therapeutics for gynaecological conditions and weight management based on end-to-end microbiome screening and functional-strain development platform.
Key Words: Microbiome & functional strains | Gynaecology, weight management & oncology | AI-empowered R&D | Commercialized assets + Phase II clinical trials
-11:30-11:45
Project 3: Innovative medical-aesthetic products built on MDM™ cross-linked hyaluronic-acid platform and HUGRO recombinant growth-factor platform. Also for osteoarthritis treatment. Real-world-data study ongoing in Boao, Hainan.
Key Words: Medical aesthetics | Regenerative medicine | Osteoarthritis | Commercially available products | Ongoing real-world-evidence study in Boao (Hainan)
-11:45-12:00
Project 4: Central-nervous-system-Focused innovative-drug R&D platform covering neurodegenerative diseases, rare diseases and tumour immunology.
Key Words: CNS | Commercially launched products | Parkinson’s disease | Phase II clinical trials
12:00-13:00 Lunch Break
13:00-13:30
Introduction to Korea's Clinical Trial Sites & Early-Phase Ecosystem
Speaker: Professor Seunghwan Lee, Seoul National University Hospital
13:30-14:30
Innovation Project Roadshows by 4 Korean Companies (15 minutes per company)
-13:30-13:45
Project 5: Low-toxicity ADC and bispecific-antibody development based on proprietary Stealth-Body Fc-silencing antibody platform.
Key Words: Antibody therapeutics | Fc-silencing technology platform | Pre-clinical stage
-13:45-14:00
Project 6: Precision novel drugs for atopic dermatitis built on AI-driven drug-discovery workflow and acyl-hydrazone small-molecule library. IND filing underway in Korea.
Key Words: AI-driven drug discovery | Small molecules | Atopic dermatitis | IND-filing stage (Korea)
-14:00-14:15
Project 7: Integrated novel-drug R&D platform for alopecia built on alopecia-related genomics and single-cell-sequencing technology, covering cell-therapy, antibody-therapy and antisense-oligonucleotide modalities.
Key Words: Alopecia treatment | Cell therapy, antibody therapy & antisense-oligonucleotide therapeutics | Phase II clinical trials
-14:15-14:30
Project 8: Multi-antigen-retargeting oncolytic HSV platform for peritoneal metastatic solid tumours; combinable with PD-1/PD-L1 inhibitors.
Key Words:Oncolytic virus | Solid tumour | IND-filing stage
14:30-14:40 Coffee Break
14:40-15:40 Innovation Project Roadshows by 4 Korean Companies (15 minutes per company)
-14:40-14:55
Project 9: Research programmes for metabolic disorders such as obesity and osteoarthritis based on SPID platform and PPI Landscape® antibody-engineering technology platform (long-acting GIPR-antagonist antibody).
Key Words: Long-acting GIPR-antagonist antibody | Metabolic diseases | Osteoarthritis | Pre-clinical stage
-14:55-15:10
Project 10: Platform for development and commercialization of mitochondria as therapeutics. Indications include polymyositis & dermatomyositis (Phase II ongoing), Parkinson’s disease, hearing loss, ophthalmic disorders, oncology and CNS diseases (pre-clinical).
Key Words: Antibody-conjugated mitochondria | Polymyositis & dermatomyositis (Phase II ongoing) | Parkinson’s disease | Hearing loss | Ophthalmology | Oncology | CNS indications (pre-clinical)
-15:10-15:25
Project 11: NK/CAR-cell immunotherapy; differentiated pipeline covering human solid-tumour CGT and veterinary oncology immunotherapeutics. Human programme in Phase IIa; veterinary oncology product already commercialized.
Key Words: Cell therapy | Human solidtumour indications | Veterinary oncology immunotherapy | Human programme in Phase IIa | Veterinary product commercially available
-15:25-15:40
Project 12: Proprietary microsphere-technology platform for long-acting injectable small-molecule improved-innovative drugs; covering CNS disorders, metabolic diseases and veterinary drugs.
Key Words: Long-acting microsphere technology platform | Improved-innovative drugs | CNS | Metabolic diseases | Veterinary pharmaceuticals
15:40-16:00
Project Discussion / Q&A / Conference Summary
16:00-17:40
1-on-1 Business Meetings (Please confirm your appointment via Angine Glonal Conference System)